180 Life Sciences Corp.
(ATNF)
undefined
undefined%
At close: undefined
1.90
-1.55%
After-hours Dec 13, 2024, 07:44 PM EST
Company Description
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases.
Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.
The company was incorporated in 2016 and is headquartered in Palo Alto, California.
180 Life Sciences Corp.
| Country | United States |
| IPO Date | Jun 27, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Sir Marc Feldmann Ph.D. |
Contact Details
Address: Building 4 Palo Alto, California United States | |
| Website | https://180lifesciences.com |
Stock Details
| Ticker Symbol | ATNF |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001690080 |
| CUSIP Number | 68236V104 |
| ISIN Number | US68236V3024 |
| Employer ID | 81-3832378 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder & Director |
| Jason Assad | Director of IR |
| Prof. Jagdeep Nanchahal M.D., Ph.D. | Co-Founder & Chairman of Clinical Advisory Board |
| Sir Marc Feldmann Ph.D. | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 3 | Filing |
| Dec 04, 2024 | 8-K | Current Report |
| Nov 15, 2024 | S-1 | Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | ARS | Filing |
| Nov 12, 2024 | DEFA14A | Filing |
| Nov 12, 2024 | DEF 14A | Filing |
| Oct 31, 2024 | 8-K | Current Report |